Developed under the direction and sponsorship of Gilead Sciences Europe Ltd. For healthcare professionals only.
At the 19th European AIDS Clinical Society Conference (EACS), Gilead Sciences hosted two dynamic symposia, discussing the importance of treatment selection for achieving long-term success, as well as exploring developments in antiretroviral therapy (ART) that are helping clinicians to avoid and manage antiretroviral drug resistance.
An esteemed panel of international experts delved into these important topics, and responded to the first-hand accounts of community members on their journeys, perspectives and aspirations.
The Great Britain and Northern Ireland/Ireland Prescribing Information for Gilead HIV medicines referenced on this site are found below:
Click here for Biktarvy®▼(BIC/FTC/TAF) GB Prescribing Information
Click here for Biktarvy® (BIC/FTC/TAF) Northern Ireland and Ireland Prescribing Information
Click here for Descovy®▼(FTC/TAF) GB Prescribing Information
Click here for Descovy® (FTC/TAF) Northern Ireland and Ireland Prescribing Information
Click here for Sunlenca®▼ solution for injection (LEN) UK Prescribing Information
Click here for Sunlenca®▼ film coated tablets (LEN) UK Prescribing Information
Click here for Tybost GB Prescribing Information
Click here for Tybost Northern Ireland and Ireland Prescribing Information
Symposium 1 – Treatment Selection for Long-Term Success: A Question of Empowerment
Watch a summary of the symposium highlights below, as our panel of international experts discussed the importance of treatment selection for long-term success, guided by first-hand testimonials from people with HIV. They focused on the help that should be provided to patients on their journey by clinicians. Our scientific faculty’s discussion was complemented by the voices of community collaborators, D’Eva (US), Grzegorz Jezierski (Poland) and Mario Cascio (Italy).
Sessions included:
- The shift to long-term success: What has changed for people with HIV?
- Sustained undetectable viral load: The starting point for treatment success
- Long-term safety, tolerability and monitoring – what does this mean?
- An optimised quality of life for all: The final goal for long-term success
A message from Cal Cohen
Speakers
Cal Cohen (Chair)
Executive Director, Global HIV Medical Affairs Department, Gilead Sciences, London, UK
Mara Boffito (Panellist)
Consultant Physician, Chelsea and Westminster Hospital and Imperial College London, UK
Giovanni Guaraldi (Panellist)
Full Professor of Infectious Disease, University of Modena and Reggio Emilia, Italy
Symposium 2 – ART Resistance: A Question of Innovation
Watch a summary of the symposium highlights below, as our panel of international experts explored the antiretroviral developments enabling us to achieve virologic success in people with multi-drug resistance, and mitigate resistance emergence in the patients of tomorrow. These sessions featured live discussions between an expert scientific faculty responding to real-life testimonies from people within the community: D’Eva (US) and Ronald Lightsey (US).
Sessions included:
- Exploring the priorities for ensuring treatment success in diverse populations initiating ART
- Stories of real-world success in adults with multidrug resistant HIV-1 infection
- Highlighting the progress made in ensuring virologic success in people with HIV switching ART
A message from Sorana Segal-Maurer
Speakers
Sorana Segal-Maurer (Chair)
Director of Infectious Diseases, NewYork-Presbyterian Queens, New York, USA, and Professor of Clinical Medicine, Weill Cornell Medicine, New York, New York, USA
Antonella Castagna (Panellist)
Head of the Infectious Diseases Clinic, Vita-Salute San Raffaele University, Milan, Italy
Graeme Moyle (Panellist)
Consultant Physician, Clinical Researcher and HIV Specialist, Chelsea and Westminster Hospital, London, UK
These promotional meetings were organised and funded by Gilead Sciences Europe Ltd.
Content is intended for healthcare professionals only
IHQ-PTF-0044 | November 2023
Adverse events should be reported. For Great Britain and Northern Ireland, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App store or Google Play store).
Adverse events should be reported to Gilead to [email protected] or +44(0) 1223 897500.
For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +35316764971. Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.
